Abstract
Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis.
Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa.
Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series.
The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
Keywords: Inflammation, immuno-mediated disease, anti-TNF-alpha, off-label use.
Current Drug Safety
Title:Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Volume: 11 Issue: 1
Author(s): Giulia Ganzetti, Anna Campanati, E. Molinelli and A. Offidani
Affiliation:
Keywords: Inflammation, immuno-mediated disease, anti-TNF-alpha, off-label use.
Abstract: Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis.
Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa.
Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series.
The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
Export Options
About this article
Cite this article as:
Ganzetti Giulia, Campanati Anna, Molinelli E. and Offidani A., Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014121732
DOI https://dx.doi.org/10.2174/1574886310666151014121732 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Effect of Canagliflozin, an SGLT2 Inhibitor, in Comparison with Atorvastatin on Dexamethasone-Induced Hepatic Steatosis in Albino Rats
Current Drug Therapy Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Synthesis of Quinazolines as Tyrosine Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
Current Drug Targets Structure and Function of the Intercellular Junctions: Barrier of Paracellular Drug Delivery
Current Pharmaceutical Design Thyroid Ultrasound and Other Imaging Procedures in the Pediatric Age
Current Pediatric Reviews Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism HSF1 as a Cancer Biomarker and Therapeutic Target
Current Cancer Drug Targets Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy The Chemistry and Pharmacology of Genistein
The Natural Products Journal Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress
Current Drug Targets Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Antioxidant Therapeutic Approaches Toward Amelioration of the Pulmonary Pathophysiological Damaging Effects of Ionizing Irradiation
Current Respiratory Medicine Reviews